Ventripoint Diagnostics Ltd(VPT-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.100
Day High0.105
Open:0.100
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
Newswire.ca
Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
GlobeNewswire
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
Newswire.ca
The $59B Quiet Shift Reshaping How Patients Access Care
Newswire.ca
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
Newswire.ca
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
Newswire.ca
The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
GlobeNewswire
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
GlobeNewswire
The Quiet Shift Replacing Million-Dollar Heart Scanners With Software
Newswire.ca
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
Newswire.ca
How Decentralized AI is Unlocking Value in Cardiac Diagnostics
Newsfile
Upcoming Meeting Dates - March 23, 2026
Newswire.ca
Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes
Newsfile
CEO.CA's Inside the Boardroom: Why Ventripoint is the Most Profitable "Bolt-On" Solution for Modern Hospitals
GlobeNewswire
THE SIGNAL ARCHITECTURE: 5 Stocks Calibrating the 2026 Infrastructure Cycle
GlobeNewswire
THE SOVEREIGNTY DOCTRINE: 5 Assets Locking Down the 2026 Survival Cycle
Newswire.ca
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
BayStreet.ca
The 2026 Healthcare Reset: Subscription Economics Meets MRI-Grade AI Precision
Newswire.ca
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market

Profile

VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.